Alternative splicing of the RAGE cytoplasmic domain regulates cell signaling and function

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Jules, Joel ^a   Maiguel, Dony ^a   Hudson, Barry I ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE;

ALTERNATIVE RNA SPLICING; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN; CARCINOGENESIS; CELL ADHESION; CELL FUNCTION; CELL INVASION; CELL MEMBRANE; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; GENE; GENE EXPRESSION; GLIOMA CELL; HEART; HUMAN; HUMAN TISSUE; KIDNEY; LUNG; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; RAGE GENE; RAT; SIGNAL TRANSDUCTION;

ALTERNATIVE SPLICING; ANIMALS; CELL LINE, TUMOR; HUMANS; MICE; ORGAN SPECIFICITY; PROTEIN STRUCTURE, TERTIARY; RATS; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION;

EID: 84892506431     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078267     Document Type: Article

References (57)

1. Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, et al. (2000) Blockage of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 405: 354-360.
2. Kalea AZ, See F, Harja E, Arriero M, Schmidt AM, et al. (2010) Alternatively spliced RAGEv1 inhibits tumorigenesis through suppression of JNK signaling. Cancer Res 70: 5628-5638.
3. Kalea AZ, Schmidt AM, Hudson BI (2009) RAGE: a novel biological and genetic marker for vascular disease. Clin Sci (Lond) 116: 621-637.
4. Logsdon CD, Fuentes MK, Huang EH, Arumugam T (2007) RAGE and RAGE ligands in cancer. Curr Mol Med 7: 777-789.
5. Hofmann MA, Drury S, Fu CF, Qu W, Taguchi A, et al. (1999) RAGE mediates a novel proinflammatory axis: a central cell surface receptor for s100/ calgranulin polypeptides. Cell 97: 889-901.
6. Hori O, Brett J, Slattery T, Cao R, Zhang J, et al. (1995) The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of RAGE and amphoterin in the developing nervous system. J Biol Chem 270: 25752-25761.
7. Hsieh HL, Schafer BW, Sasaki N, Heizmann CW (2003) Expression analysis of S100 proteins and RAGE in human tumors using tissue microarrays. Biochem Biophys Res Commun 307: 375-381.
8. Bhawal UK, Ozaki Y, Nishimura M, Sugiyama M, Sasahira T, et al. (2005) Association of expression of receptor for advanced glycation end products and invasive activity of oral squamous cell carcinoma. Oncology 69: 246-255.
9. Ishiguro H, Nakaigawa N, Miyoshi Y, Fujinami K, Kubota Y, et al. (2005) Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development. Prostate 64: 92-100.
10. Sasahira T, Akama Y, Fujii K, Kuniyasu H (2005) Expression of receptor for advanced glycation end products and HMGB1/amphoterin in colorectal adenomas. Virchows Arch 446: 411-415.
11. Kuniyasu H, Chihara Y, Takahashi T (2003) Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer. Oncol Rep 10: 445-448.
12. Kuniyasu H, Oue N, Wakikawa A, Shigeishi H, Matsutani N, et al. (2002) Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol 196: 163-170.
13. Hudson BI, Kalea AZ, Arriero MD, Harja E, Boulanger E, et al. (2008) Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42. J Biol Chem 283: 34457-34468.
14. Kislinger T, Fu C, Huber C, Qu W, Taguchi A, et al. (1999) N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 274: 31740-31749.
15. Huang JS, Guh JY, Chen HC, Hung WC, Lai YH, et al. (2001) Role of receptor for advanced glycation end-product (RAGE) and the JAK/STAT-signaling pathway in AGE-induced collagen production in NRK-49F cells. J Cell Biochem 81: 102-113.
16. Yeh CH, Sturgis L, Haidacher J, Zhang XN, Sherwood SJ, et al. (2001) Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kappaB transcriptional activation and cytokine secretion. Diabetes 50: 1495-1504.
17. Lander HM, Tauras JM, Ogiste JS, Hori O, Moss RA, et al. (1997) Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 272: 17810-17814.
18. Huttunen HJ, Fages C, Rauvala H (1999) Receptor for Advanced Glycation End Products (RAGE)-mediated Neurite Outgrowth and Activation of NF-kappa B Require the Cytoplasmic Domain of the Receptor but Different Downstream Signaling Pathways. J Biol Chem 274: 19919-19924.
19. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, et al. (1992) Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 267: 14998-15004.
20. Sakaguchi T, Yan SF, Yan SD, Belov D, Rong LL, et al. (2003) Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest 111: 959-972.
21. Ishihara K, Tsutsumi K, Kawane S, Nakajima M, Kasaoka T (2003) The receptor for advanced glycation end-products (RAGE) directly binds to ERK by a D-domain-like docking site. FEBS Lett 550: 107-113.
22. Sakaguchi M, Murata H, Yamamoto K, Ono T, Sakaguchi Y, et al. (2011) TIRAP, an adaptor protein for TLR2/4, transduces a signal from RAGE phosphorylated upon ligand binding. PLoS ONE 6: e23132. 10.1371/journal.pone. 0023132 [doi]; PONE-D-11-05047 [pii].
23. Yamamoto K, Murata H, Putranto EW, Kataoka K, Motoyama A, et al. (2013) DOCK7 is a critical regulator of the RAGE-Cdc42 signaling axis that induces formation of dendritic pseudopodia in human cancer cells. Oncol Rep 29: 1073-1079. 10.3892/or.2012.2191 [doi].
24. Yan HC, Baldwin HS, Sun J, Buck CA, Albelda SM, et al. (1995) Alternative splicing of a specific cytoplasmic exon alters the binding characteristics of murine platelet/endothelial cell adhesion molecule-1 (PECAM-1). J Biol Chem 270: 23672-23680.
25. Gaur S, Shively JE, Yen Y, Gaur RK (2008) Altered splicing of CEACAM1 in breast cancer: identification of regulatory sequences that control splicing of CEACAM1 into long or short cytoplasmic domain isoforms. Mol Cancer 7: 46. 1476-4598-7-46 [pii];10.1186/1476-4598-7-46 [doi].
26. Malherbe P, Richards JG, Gaillard H, Thompson A, Diener C, et al. (1999) cDNA cloning of a novel secreted isoform of the human receptor for advanced glycation end products and characterization of cells co-expressing cell-surface scavenger receptors and Swedish mutant amyloid precursor protein. Brain Res Mol Brain Res 71: 159-170.
27. Yonekura H, Yamamoto Y, Sakurai S, Petrova RG, Abedin MJ, et al. (2003) Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 370: 1097-1109.
28. Schlueter C, Hauke S, Flohr AM, Rogalla P, Bullerdiek J (2003) Tissue-specific expression patterns of the RAGE receptor and its soluble forms - a result of regulated alternative splicing? Biochim Biophys Acta 1630: 1-6.
29. Park IH, Yeon SI, Youn JH, Choi JE, Sasaki N, et al. (2004) Expression of a novel secreted splice variant of the receptor for advanced glycation end products (RAGE) in human brain astrocytes and peripheral blood mononuclear cells. Mol Immunol 40: 1203-1211.
30. Hudson BI, Carter AM, Harja E, Kalea AZ, Arriero M, et al. (2008) Identification, classification, and expression of RAGE gene splice variants. FASEB J 22: 1572-1580.
31. Kalea AZ, Reiniger N, Yang H, Arriero M, Schmidt AM, et al. (2009) Alternative splicing of the murine receptor for advanced glycation end-products (RAGE) gene. FASEB J 23: 1766-1774.
32. Sterenczak KA, Willenbrock S, Barann M, Klemke M, Soller JT, et al. (2009) Cloning, characterisation, and comparative quantitative expression analyses of receptor for advanced glycation end products (RAGE) transcript forms. Gene 434: 35-42.
33. Harashima A, Yamamoto Y, Cheng C, Tsuneyama K, Myint KM, et al. (2006) Identification of mouse orthologue of endogenous secretory receptor for advanced glycation end-products: structure, function and expression. Biochem J 396: 109-115.
34. Ke N, Albers A, Claassen G, Yu DH, Chatterton JE, et al. (2004) One-week 96-well soft agar growth assay for cancer target validation. Biotechniques 36: 826-3.
35. Albini A, Benelli R (2007) The chemoinvasion assay: a method to assess tumor and endothelial cell invasion and its modulation. Nat Protoc 2: 504-511. nprot.2006.466 [pii];10.1038/nprot.2006.466 [doi].
36. Kalea AZ, Schmidt AM, Hudson BI (2012) Alternative splicing of RAGE: roles in biology and disease. Front Biosci 17: 2756-2770. 3884 [pii].
37. Grobben B, De Deyn pp., Slegers H (2002) Rat C6 glioma as experimental model system for the study of glioblastoma growth and invasion. Cell Tissue Res 310: 257-270.
38. Arumugam T, Ramachandran V, Gomez SB, Schmidt AM, Logsdon CD (2012) S100P-derived RAGE antagonistic peptide reduces tumor growth and metastasis. Clin Cancer Res 18: 4356-4364. 1078-0432.CCR-12-0221 [pii];10.1158/1078-0432. CCR-12-0221 [doi].
39. Kang R, Loux T, Tang D, Schapiro NE, Vernon P, et al. (2012) The expression of the receptor for advanced glycation endproducts (RAGE) is permissive for early pancreatic neoplasia. Proc Natl Acad Sci U S A 109: 7031-7036. 1113865109 [pii];10.1073/pnas.1113865109 [doi].
40. Kang R, Tang D, Schapiro NE, Livesey KM, Farkas A, et al. (2010) The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival. Cell Death Differ 17: 666-676. cdd2009149 [pii];10.1038/cdd.2009.149 [doi].
41. Xiong F, Leonov S, Howard AC, Xiong S, Zhang B, et al. (2011) Receptor for advanced glycation end products (RAGE) prevents endothelial cell membrane resealing and regulates F-actin remodeling in a beta-catenin-dependent manner. J Biol Chem 286: 35061-35070. M111.261073 [pii];10.1074/jbc.M111.261073 [doi].
42. Zhou Z, Immel D, Xi CX, Bierhaus A, Feng X, et al. (2006) Regulation of osteoclast function and bone mass by RAGE. J Exp Med 203: 1067-1080. jem.20051947 [pii];10.1084/jem.20051947 [doi].
43. Zen K, Chen CX, Chen YT, Wilton R, Liu Y (2007) Receptor for advanced glycation endproducts mediates neutrophil migration across intestinal epithelium. J Immunol 178: 2483-2490.
44. Yamagishi S, Adachi H, Nakamura K, Matsui T, Jinnouchi Y, et al. (2006) Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism 55: 1227-1231. S0026-0495(06)00174-0 [pii];10.1016/j. metabol.2006.05.007 [doi].
45. Jackel A, Deichmann M, Waldmann V, Bock M, Naher H (1999) [S-100 beta protein in serum, a tumor marker in malignant melanoma - current state of knowledge and clinical experience]. Hautarzt 50: 250-256.
46. Pietzsch J, Hoppmann S (2009) Human S100A12: a novel key player in inflammation? Amino Acids 36: 381-389. 10.1007/s00726-008-0097-7 [doi].
47. Albini A, Noonan DM (2010) The 'chemoinvasion' assay, 25 years and still going strong: the use of reconstituted basement membranes to study cell invasion and angiogenesis. Curr Opin Cell Biol 22: 677-689. S0955-0674(10)00140-7 [pii];10.1016/j.ceb.2010.08.017 [doi].
48. Stamm S, Ben-Ari S, Rafalska I, Tang Y, Zhang Z, et al. (2005) Function of alternative splicing. Gene 344: 1-20.
49. Wendt TM, Tanji N, Guo J, Kislinger TR, Qu W, et al. (2003) RAGE Drives the Development of Glomerulosclerosis and Implicates Podocyte Activation in the Pathogenesis of Diabetic Nephropathy. Am J Pathol 162: 1123-1137.
50. Wendt T, Tanji N, Guo J, Hudson BI, Bierhaus A, et al. (2003) Glucose, Glycation, and RAGE: Implications for Amplification of Cellular Dysfunction in Diabetic Nephropathy. J Am Soc Nephrol 14: 1383.
51. Rai V, Maldonado AY, Burz DS, Reverdatto S, Yan SF, et al. (2012) Signal transduction in receptor for advanced glycation end products (RAGE): solution structure of C-terminal rage (ctRAGE) and its binding to mDia1. J Biol Chem 287: 5133-5144. M111.277731 [pii];10.1074/jbc.M111.277731 [doi].
52. Zong H, Madden A, Ward M, Mooney MH, Elliott CT, et al. (2010) Homodimerization is essential for the receptor for advanced glycation end products (RAGE)-mediated signal transduction. J Biol Chem 285: 23137-23146.
53. Wei W, Lampe L, Park S, Vangara BS, Waldo GS, et al. (2012) Disulfide bonds within the C2 domain of RAGE play key roles in its dimerization and biogenesis. PLoS ONE 7: e50736. 10.1371/journal.pone.0050736 [doi]; PONE-D-12-28385 [pii].
54. Su PC, Berger BW (2012) Identifying key juxtamembrane interactions in cell membranes using AraC-based transcriptional reporter assay (AraTM). J Biol Chem 287: 31515-31526. M112.396895 [pii];10.1074/jbc.M112.396895 [doi].
55. Ma W, Lee SE, Guo J, Qu W, Hudson BI, et al. (2007) RAGE ligand upregulation of VEGF secretion in ARPE-19 cells. Invest Ophthalmol Vis Sci 48: 1355-1361. 48/3/1355 [pii];10.1167/iovs.06-0738 [doi].
56. Ma W, Rai V, Hudson BI, Song F, Schmidt AM, et al. (2012) RAGE binds C1q and enhances C1q-mediated phagocytosis. Cell Immunol 274: 72-82. S0008-8749(12)00022-6 [pii];10.1016/j.cellimm.2012.02.001 [doi].
57. Deane R, Singh I, Sagare AP, Bell RD, Ross NT, et al. (2012) A multimodal RAGE-specific inhibitor reduces amyloid beta-mediated brain disorder in a mouse model of Alzheimer disease. J Clin Invest 122: 1377-1392. 58642 [pii];10.1172/JCI58642 [doi].